Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for relapsed or treatment-refractory acute myeloid leukemia expressing t(8;21) and CD19
MOH_2019-12-22_008570Phase 3Not yet recruiting
- Sponsor
- פרופסור ארנון נגלר
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in acute myeloid leukemia (AML), sponsored by פרופסור ארנון נגלר. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2019-12-22_008570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-22_008570.